Amphastar Pharmaceuticals, Inc. (AMPH)
USD 24.42
(1.08%)
USD 24.42
(1.08%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 873.49 Million USD | 309.46% |
| 2022 | 213.32 Million USD | -5.61% |
| 2021 | 226 Million USD | 23.83% |
| 2020 | 182.51 Million USD | 14.47% |
| 2019 | 159.44 Million USD | 6.86% |
| 2018 | 149.2 Million USD | 27.16% |
| 2017 | 117.33 Million USD | 19.14% |
| 2016 | 98.48 Million USD | 4.08% |
| 2015 | 94.62 Million USD | -11.98% |
| 2014 | 107.51 Million USD | 23.29% |
| 2013 | 87.2 Million USD | 3.77% |
| 2012 | 84.03 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 901.96 Million USD | 3.26% |
| 2024 Q2 | 778.17 Million USD | -13.72% |
| 2023 Q2 | 789.03 Million USD | 250.56% |
| 2023 Q4 | 873.49 Million USD | -8.0% |
| 2023 FY | 873.49 Million USD | 309.46% |
| 2023 Q1 | 225.07 Million USD | 5.51% |
| 2023 Q3 | 949.49 Million USD | 20.34% |
| 2022 Q4 | 213.32 Million USD | -3.7% |
| 2022 Q3 | 221.53 Million USD | -1.28% |
| 2022 FY | 213.32 Million USD | -5.61% |
| 2022 Q1 | 236.71 Million USD | 4.74% |
| 2022 Q2 | 224.41 Million USD | -5.2% |
| 2021 Q3 | 221.5 Million USD | 11.58% |
| 2021 Q2 | 198.52 Million USD | 1.92% |
| 2021 Q1 | 194.77 Million USD | 6.72% |
| 2021 FY | 226 Million USD | 23.83% |
| 2021 Q4 | 226 Million USD | 2.03% |
| 2020 Q2 | 157.62 Million USD | 5.46% |
| 2020 Q3 | 162.75 Million USD | 3.26% |
| 2020 Q4 | 182.51 Million USD | 12.14% |
| 2020 FY | 182.51 Million USD | 14.47% |
| 2020 Q1 | 149.45 Million USD | -6.26% |
| 2019 Q1 | 164.45 Million USD | 10.22% |
| 2019 FY | 159.44 Million USD | 6.86% |
| 2019 Q4 | 159.44 Million USD | 4.91% |
| 2019 Q3 | 151.98 Million USD | -10.08% |
| 2019 Q2 | 169.01 Million USD | 2.77% |
| 2018 Q1 | 122.67 Million USD | 4.55% |
| 2018 FY | 149.2 Million USD | 27.16% |
| 2018 Q4 | 149.2 Million USD | 7.05% |
| 2018 Q3 | 139.37 Million USD | 6.29% |
| 2018 Q2 | 131.12 Million USD | 6.88% |
| 2017 Q4 | 117.33 Million USD | 9.55% |
| 2017 FY | 117.33 Million USD | 19.14% |
| 2017 Q1 | 110.05 Million USD | 11.75% |
| 2017 Q2 | 110.68 Million USD | 0.57% |
| 2017 Q3 | 107.11 Million USD | -3.23% |
| 2016 Q1 | 98.42 Million USD | 4.01% |
| 2016 FY | 98.48 Million USD | 4.08% |
| 2016 Q4 | 98.48 Million USD | -1.89% |
| 2016 Q3 | 100.38 Million USD | -0.73% |
| 2016 Q2 | 101.12 Million USD | 2.74% |
| 2015 Q3 | 111.24 Million USD | -2.13% |
| 2015 Q2 | 113.66 Million USD | -3.03% |
| 2015 Q1 | 117.22 Million USD | 9.03% |
| 2015 FY | 94.62 Million USD | -11.98% |
| 2015 Q4 | 94.62 Million USD | -14.94% |
| 2014 Q4 | 107.51 Million USD | -8.9% |
| 2014 Q3 | 118.01 Million USD | 7.75% |
| 2014 Q2 | 109.52 Million USD | 17.06% |
| 2014 Q1 | 93.56 Million USD | 7.3% |
| 2014 FY | 107.51 Million USD | 23.29% |
| 2013 Q3 | 96.6 Million USD | 0.0% |
| 2013 Q4 | 87.2 Million USD | -9.73% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | 87.2 Million USD | 3.77% |
| 2012 Q4 | 84.03 Million USD | 0.0% |
| 2012 FY | 84.03 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 7.848% |
| Embecta Corp. | 2.03 Billion USD | 57.1% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -85.19% |
| Dynavax Technologies Corporation | 375.02 Million USD | -132.916% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -32.189% |
| Pacira BioSciences, Inc. | 704.25 Million USD | -24.03% |
| PainReform Ltd. | 2.69 Million USD | -32359.718% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -432.925% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -14127.165% |
| SCYNEXIS, Inc. | 55.45 Million USD | -1475.277% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -9397.966% |
| Cosmos Health Inc. | 30.25 Million USD | -2787.333% |
| Journey Medical Corporation | 56.49 Million USD | -1446.029% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -14127.165% |
| Safety Shot Inc | 3.89 Million USD | -22342.989% |
| Alpha Teknova, Inc. | 38.55 Million USD | -2165.806% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -538.186% |
| Bright Green Corporation | 6.43 Million USD | -13467.523% |
| Procaps Group, S.A. | 462.06 Million USD | -89.041% |
| Theratechnologies Inc. | 98.63 Million USD | -785.543% |
| Harrow Health, Inc. | 241.75 Million USD | -261.315% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -9875.914% |
| Biofrontera Inc. | 23.13 Million USD | -3674.973% |
| DURECT Corporation | 30.4 Million USD | -2772.759% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -79.192% |
| Cronos Group Inc. | 43.73 Million USD | -1897.186% |
| OptiNose, Inc. | 194.33 Million USD | -349.477% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | -6.866% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1703.057% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -4063.818% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -381.628% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -23056.415% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -1563.279% |
| Radius Health, Inc. | 804.29 Million USD | -8.604% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -6250.661% |
| ProPhase Labs, Inc. | 42.54 Million USD | -1953.147% |
| Phibro Animal Health Corporation | 725.54 Million USD | -20.391% |
| Procaps Group S.A. | 462.06 Million USD | -89.041% |
| Alvotech | 1.88 Billion USD | 53.601% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -6129.432% |
| Viatris Inc. | 27.21 Billion USD | 96.791% |
| Rockwell Medical, Inc. | 30.88 Million USD | -2728.479% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -866.476% |
| SIGA Technologies, Inc. | 57.97 Million USD | -1406.609% |
| Tilray Brands, Inc. | 892.11 Million USD | 2.088% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -297.403% |
| Shineco, Inc. | 47.6 Million USD | -1735.0% |
| PetIQ, Inc. | 645.22 Million USD | -35.377% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -397824.031% |
| Incannex Healthcare Limited | 5.83 Million USD | -14882.693% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 14.313% |
| Alimera Sciences, Inc. | 107.35 Million USD | -713.655% |
| Silver Spike Investment Corp. | 3 Million USD | -28921.264% |
| Assertio Holdings, Inc. | 148.41 Million USD | -488.542% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -45971.051% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -3997.862% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -12332.266% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -10187.825% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -403.781% |
| Hempacco Co., Inc. | 18.82 Million USD | -4540.698% |
| Talphera, Inc. | 6.29 Million USD | -13786.979% |
| Alvotech | 1.88 Billion USD | 53.601% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -406.078% |
| Lantheus Holdings, Inc. | 835.25 Million USD | -4.578% |
| Currenc Group, Inc. | 177.67 Million USD | -391.621% |
| Kamada Ltd. | 109.96 Million USD | -694.312% |
| Indivior PLC | 1.95 Billion USD | 55.234% |
| Evoke Pharma, Inc. | 9.64 Million USD | -8953.519% |
| Flora Growth Corp. | 17.22 Million USD | -4971.949% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -10187.825% |
| Evolus, Inc. | 209.68 Million USD | -316.569% |
| HUTCHMED (China) Limited | 536.38 Million USD | -62.847% |
| Akanda Corp. | 12.66 Million USD | -6794.774% |